最新の財務諸表(Form-10K)によると、Medx Health Corpの総資産は$0で、純損失は$-3です。
MDXHFの主要な財務比率は何ですか?
Medx Health Corpの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Medx Health Corpの収益はセグメントまたは地域別にどのように分けられていますか?
Medx Health Corp の最大収益セグメントは Phototherapeutic Lasers で、最新の利益発表における収益は 293,532 です。地域別に見ると、Canada が Medx Health Corp の主要市場であり、収益は 301,018 です。
Medx Health Corpは収益を上げていますか?
いいえ、最新の財務諸表によると、Medx Health Corpの純損失は$-3です。
Medx Health Corpに負債はありますか?
はい、Medx Health Corpの負債は9です。
Medx Health Corpの発行済株式数は何株ですか?
Medx Health Corpの総発行済株式数は272.31株です。
主要データ
前終値
$0.044
始値
$0.045
当日レンジ
$0.044 - $0.045
52週レンジ
$0.0008 - $0.05
取引高
60.0K
平均取引高
2.9K
配当利回り
--
1株当たり利益(TTM)
-0.01
時価総額
$14.4M
MEDX HEALTH CORPとは何ですか?
MedX Health Corp. engages in the development, manufacture, and sale of medical device and software. The company is headquartered in Mississauga, Ontario. The company went IPO on 2008-02-12. The company develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. The company focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.